Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Larimar Therapeutics (LRMR) Notes Payables (2016 - 2020)

Larimar Therapeutics (LRMR) has disclosed Notes Payables for 6 consecutive years, with $7.3 million as the latest value for Q3 2019.

  • For the quarter ending Q3 2019, Notes Payables fell 64.52% year-over-year to $7.3 million, compared with a TTM value of $7.3 million through Sep 2019, down 64.52%, and an annual FY2018 reading of $5.5 million, down 72.72% over the prior year.
  • Notes Payables was $7.3 million for Q3 2019 at Larimar Therapeutics, roughly flat from $7.3 million in the prior quarter.
  • Across five years, Notes Payables topped out at $20.5 million in Q3 2018 and bottomed at $1.3 million in Q3 2017.
  • Average Notes Payables over 5 years is $6.3 million, with a median of $3.1 million recorded in 2016.
  • Peak annual rise in Notes Payables hit 1516.72% in 2018, while the deepest fall reached 72.72% in 2018.
  • Year by year, Notes Payables stood at $2.9 million in 2015, then increased by 22.24% to $3.6 million in 2016, then surged by 457.26% to $20.0 million in 2017, then crashed by 72.72% to $5.5 million in 2018, then skyrocketed by 33.33% to $7.3 million in 2019.
  • Business Quant data shows Notes Payables for LRMR at $7.3 million in Q3 2019, $7.3 million in Q2 2019, and $7.3 million in Q1 2019.